Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Freiburg Im Breisgau – page 32

534 clinical trials in Freiburg Im Breisgau, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Freiburg Im Breisgau at a glance
534
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

534 trials in Freiburg Im Breisgau

Open in trial search

Study of decitabine and cedazuridine combination in patients with lower-risk myelodysplastic syndromes

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cedazuridine
  • Sponsor:Taiho Oncology Inc.

Rectal cancer

Not recruiting

Study Comparing Short Course Radiotherapy and Chemoradiotherapy with Fluorouracil, Calcium Folinate, and Capecitabine for Intermediate and High-Risk Rectal Cancer Patients

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Goethe University Frankfurt

Parkinson's disease

Not recruiting

Study on the Safety and Effects of Fasudil Hydrochloride for Patients with Parkinson's Disease

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Fasudil Hydrochloride
  • Sponsor:Klinikum rechts der Isar der TU Muenchen AöR

Malignant melanoma

Not recruiting

Study on Fianlimab and Cemiplimab for Adults with Resectable Stage III and IV Melanoma

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab
  • Sponsor:Regeneron Pharmaceuticals Inc.

Breast cancer+4

Not recruiting

Study Comparing Ribociclib and Endocrine Therapy to Chemotherapy for Patients with Intermediate-Risk HR+/HER2- Early Breast Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ribociclib
  • Sponsor:WSG Women's Cancer Study Group GmbH

Metastatic neoplasm+1

Not recruiting

Study on Treating Advanced Cancers with BRAF Mutations Using Sorafenib and Trametinib for Patients with Impaired Kinase Activity

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sorafenib
  • Sponsor:Medical Center - University Of Freiburg

Malignant glioma

Not recruiting

Study of tovorafenib versus standard chemotherapy as first treatment for children with low-grade glioma with RAF gene changes

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Carboplatin
  • Sponsor:Day One Biopharmaceuticals Inc.

Acoustic neuroma

Not recruiting

Study on Nimodipine for Hearing Preservation in Patients Undergoing Acoustic Schwannoma Surgery

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Nimodipine
  • Sponsor:Martin-Luther-Universitaet Halle-Wittenberg
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate
  • Sponsor:University Of Cologne

Adenocarcinoma gastric+1

Not recruiting

Study Comparing Ramucirumab with Irinotecan, Leucovorin, and 5-FU or Paclitaxel for Patients with Advanced Stomach or Gastroesophageal Cancer After Previous Chemotherapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Plasma cell myeloma

Not recruiting

Comparison of intravenous versus subcutaneous isatuximab with lenalidomide, bortezomib and dexamethasone in newly diagnosed multiple myeloma patients eligible for transplant

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Universitaetsklinikum Heidelberg AöR

Hidradenitis

Not recruiting

Study of lutikizumab compared to placebo in adults and adolescents (age 12 and older) with moderate to severe Hidradenitis Suppurativa

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Lutikizumab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Freiburg Im Breisgau

What the registry says about research in the country

01 Oncology

Neoplasms research in Freiburg covers a broad mix of cancer studies, from lung and colorectal cancer to breast, endometrial, prostate, sarcoma, and childhood leukemia. These trials are mainly focused on testing new treatments, improving cancer control, and refining treatment combinations for better outcomes.

  • Advanced and metastatic solid tumors
  • ALK+ NSCLC and small cell lung cancer
  • HER2+ early breast cancer and HER2-expressing endometrial cancer
  • Metastatic colorectal cancer, prostate cancer, sarcoma, and pediatric leukemia

Several studies are evaluating whether new cancer therapies can improve survival, delay recurrence, or support earlier and more effective treatment choices.

02 Neurology and Stroke

Clinical trials in nervous system diseases are examining acute stroke care and childhood cerebrovascular disorders. The research aims to improve recovery after stroke, reduce recurrence, and assess new treatment options for difficult cases.

  • Acute ischemic stroke with incomplete reperfusion
  • Stroke in children with focal cerebral arteriopathy
  • Patients using direct oral anticoagulants who experience stroke

This area includes studies of thrombolysis and anti-inflammatory treatment strategies designed to improve functional outcomes and neurological recovery.

03 Respiratory and Critical Care

Freiburg also hosts studies in respiratory tract diseases and neonatal lung care, with a strong focus on preterm infants and oxygen-related support. These trials are evaluating ways to improve breathing outcomes and reduce complications in vulnerable newborns.

  • Respiratory distress syndrome in preterm infants
  • Extremely premature infants needing respiratory support
  • Small cell lung cancer treatment combinations

In addition to newborn care, lung cancer research is testing whether newer oncology approaches can improve disease control in advanced respiratory malignancies.

04 Pediatrics and Neonatal Medicine

A major part of the research landscape in Freiburg is dedicated to congenital, hereditary, and neonatal diseases. These studies focus on safer care for preterm infants, childhood stroke, and pediatric leukemia, with the goal of improving long-term health and survival.

  • Preterm infants with very low gestational age
  • Childhood leukemia
  • Focal cerebral arteriopathy in children
  • Long-term respiratory and neurological outcomes

The trials are designed to support better early treatment decisions and to reduce complications that can affect development later in life.

05 Cardiology and Kidney Health

Studies in cardiovascular diseases and chronic kidney disease are exploring ways to slow disease progression and lower the risk of major heart-related events. The goal is to strengthen preventive care for people with long-term metabolic and organ-related conditions.

  • Familial hypercholesterolemia
  • Chronic kidney disease
  • Heart and kidney protection strategies

These trials are looking at whether new treatment combinations can improve long-term safety and reduce complications in high-risk patients.

06 Endocrine and Metabolic Research

Trials in hormonal diseases and related metabolic conditions are addressing disorders that affect both quality of life and long-term health. This includes research on hormone-sensitive cancers, lipid disorders, and treatment approaches linked to kidney and heart protection.

  • Metastatic hormone sensitive prostate cancer
  • Familial hypercholesterolemia
  • Metabolic support for patients with kidney disease

The studies aim to improve disease control and better tailor treatment to patients with chronic hormonal or metabolic risk factors.

07 Psychiatry and Psychology

Research in psychological phenomena includes clinical trials for ADHD in adults. These studies are focused on comparing treatment options that may help improve attention, daily functioning, and symptom control.

  • Adult patients with ADHD
  • Comparing stimulant treatment options with placebo

This area reflects an interest in evidence-based approaches for managing neurodevelopmental symptoms in adult care.

08 Dermatology and Hair Disorders

Freiburg’s clinical trials also include skin and connective tissue diseases, especially hair loss conditions. The research is evaluating new ways to improve hair growth and address androgen-related hair loss in both men and women.

  • Androgenetic alopecia in men
  • Female androgenetic alopecia
  • Testing topical and oral treatment approaches

These studies are aimed at finding more effective and better-tolerated options for common hair disorders.

09 Ear, Nose, and Throat

The city’s research portfolio includes otorhinolaryngologic diseases, with trials focused on sudden hearing loss. The main purpose is to assess whether new treatment options can improve hearing recovery more effectively than current care.

  • Idiopathic sudden sensorineural hearing loss
  • Comparing a novel ear treatment with standard steroid therapy

This work is especially relevant for rapid intervention in conditions where early treatment may influence long-term hearing outcomes.

10 Digestive and Pelvic Health

Trials in digestive system diseases include research on bowel and rectal complications related to cancer treatment. These studies aim to reduce symptoms and improve comfort for patients undergoing oncologic care.

  • Acute radiation proctitis
  • Symptoms in men treated for prostate cancer
  • Supportive care during cancer therapy

The focus is on symptom relief and improving quality of life during or after radiotherapy.

11 Male Urogenital Health

Research in male urogenital diseases includes prostate cancer studies and work on hair and hormonal conditions affecting men. The trials are testing whether new treatment strategies can improve disease control and patient well-being.

  • Metastatic prostate cancer
  • Prostate cancer with treatment-related rectal symptoms

In Freiburg, this area combines cancer research with supportive care questions that matter for everyday treatment experience.

12 Reproductive and Urinary Physiology

A smaller set of studies addresses reproductive and urinary physiological phenomena, especially kidney-related health and treatment effects that influence urinary function. These trials are aimed at better protection of organ function over time.

  • Chronic kidney disease
  • Heart-kidney protection in patients with renal risk

The research reflects growing interest in preserving both cardiovascular and urinary system health in chronic disease.

13 Immunology and Inflammation

Several Freiburg trials explore inflammatory mechanisms across different diseases, from stroke-related vessel disease to cancer and radiation injury. The main purpose is to see whether targeted anti-inflammatory or immune-based approaches can improve outcomes.

  • Focal cerebral arteriopathy
  • Acute radiation proctitis
  • Immune-based cancer vaccination strategies

This field links inflammation research with practical treatment questions in both neurology and oncology.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.